Imagine a world where a silent killer, lurking in nearly one in ten people, could be stopped in its tracks. Chronic kidney disease (CKD) affects close to a billion lives globally, often progressing unnoticed until it’s too late. But what if we could catch it early, before irreversible damage occurs? This is the bold promise of a groundbreaking innovation emerging from the University of Manitoba (UM).
Here’s the game-changer: AssureCKD, a UM-affiliated startup, is revolutionizing kidney disease diagnosis with MATLOC, a lab-on-a-chip technology that’s both rapid and affordable. Unlike traditional lab tests, which are costly and complex, MATLOC can be administered anywhere, bringing life-saving diagnostics directly to patients. This innovation is the culmination of over a decade of research led by UM’s Dr. Claudio Rigatto and Dr. Francis Lin.
And this is the part most people miss: While effective diagnostic tools exist, their inaccessibility in remote or under-resourced areas leaves millions at risk. MATLOC aims to bridge this gap, offering a simple, low-cost solution that can be used during routine doctor visits. “Kidney disease has become a massive problem, especially in Canada, where nearly one in ten people are affected,” explains Dr. Francis Lin, Professor at UM’s Departments of Physics and Astronomy and Immunology. “The urgent need for early diagnosis tools is undeniable.”
But here’s where it gets controversial: Despite the potential of MATLOC, its success hinges on widespread adoption and equitable access. Will healthcare systems prioritize preventative care over reactive treatment? And can we ensure this technology reaches those who need it most, regardless of geography or socioeconomic status?
Earlier this year, AssureCKD secured major federal funding to advance MATLOC’s development, a critical step toward making this technology a clinical and commercial reality. “As a kidney specialist, witnessing preventable kidney failure is devastating,” shares Dr. Claudio Rigatto, Professor at UM’s Department of Internal Medicine. “With MATLOC, we’re transforming screening from a costly, equipment-heavy process into a simple, affordable test that can be done in any doctor’s office.”
Here’s the bigger picture: MATLOC is currently seeking regulatory approval in Canada and the U.S., with the potential to become a global standard for kidney disease prevention. “UM’s support has been invaluable, from research operations to industry partnerships,” notes Dr. Lin. “With universally accessible screening tools, we can improve patient outcomes and significantly reduce healthcare costs for everyone.”
But let’s not forget the human impact: For communities like those in Northern Canada, where screening once required transporting hundreds of pounds of equipment and cost thousands, MATLOC represents hope. It’s not just about innovation—it’s about equity and accessibility.
Now, here’s the question we leave you with: As we push toward preventative care, how can we ensure technologies like MATLOC are not just developed, but also distributed fairly? Share your thoughts in the comments—we want to hear from you!
For more on how research is being turned into real-world impact, visit UM Partnerships and Innovation. And to learn more about AssureCKD’s journey, check out their website here. Their recent publication in Sensors and Actuators B: Chemical link details the groundbreaking progress of MATLOC—a must-read for anyone passionate about the future of healthcare.
